DK0833620T3 - FGFR3, en markør for mesenkymale progenitorceller - Google Patents

FGFR3, en markør for mesenkymale progenitorceller

Info

Publication number
DK0833620T3
DK0833620T3 DK96917640T DK96917640T DK0833620T3 DK 0833620 T3 DK0833620 T3 DK 0833620T3 DK 96917640 T DK96917640 T DK 96917640T DK 96917640 T DK96917640 T DK 96917640T DK 0833620 T3 DK0833620 T3 DK 0833620T3
Authority
DK
Denmark
Prior art keywords
fgfr3
progenitor cells
bone
marker
skeletal progenitor
Prior art date
Application number
DK96917640T
Other languages
English (en)
Inventor
Avner Yayon
Zvi Nevo
Original Assignee
Yeda Res & Dev
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Univ Ramot filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK0833620T3 publication Critical patent/DK0833620T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK96917640T 1995-06-12 1996-06-12 FGFR3, en markør for mesenkymale progenitorceller DK0833620T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13795P 1995-06-12 1995-06-12
PCT/IL1996/000010 WO1996041620A1 (en) 1995-06-12 1996-06-12 Fgfr3 as a marker for mesenchymal skeletal progenitor cells

Publications (1)

Publication Number Publication Date
DK0833620T3 true DK0833620T3 (da) 2003-01-13

Family

ID=21690089

Family Applications (2)

Application Number Title Priority Date Filing Date
DK96917641T DK0836380T3 (da) 1995-06-12 1996-06-12 FGF9 som en specifik ligand for FGFR3
DK96917640T DK0833620T3 (da) 1995-06-12 1996-06-12 FGFR3, en markør for mesenkymale progenitorceller

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK96917641T DK0836380T3 (da) 1995-06-12 1996-06-12 FGF9 som en specifik ligand for FGFR3

Country Status (12)

Country Link
US (2) US6447783B1 (da)
EP (3) EP1342476A3 (da)
JP (3) JP3673281B2 (da)
CN (1) CN1195982A (da)
AT (2) ATE225652T1 (da)
AU (2) AU715996B2 (da)
CA (2) CA2224229A1 (da)
DE (2) DE69624239T2 (da)
DK (2) DK0836380T3 (da)
ES (2) ES2173289T3 (da)
IL (2) IL122473A (da)
WO (2) WO1996041620A1 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468075B2 (en) 2001-05-25 2008-12-23 Conformis, Inc. Methods and compositions for articular repair
US9603711B2 (en) 2001-05-25 2017-03-28 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US8882847B2 (en) 2001-05-25 2014-11-11 Conformis, Inc. Patient selectable knee joint arthroplasty devices
US9020788B2 (en) 1997-01-08 2015-04-28 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US8556983B2 (en) 2001-05-25 2013-10-15 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs and related tools
US7534263B2 (en) 2001-05-25 2009-05-19 Conformis, Inc. Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty
US7618451B2 (en) 2001-05-25 2009-11-17 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty
US8083745B2 (en) 2001-05-25 2011-12-27 Conformis, Inc. Surgical tools for arthroplasty
US8480754B2 (en) 2001-05-25 2013-07-09 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US8545569B2 (en) 2001-05-25 2013-10-01 Conformis, Inc. Patient selectable knee arthroplasty devices
US8735773B2 (en) 2007-02-14 2014-05-27 Conformis, Inc. Implant device and method for manufacture
US8771365B2 (en) 2009-02-25 2014-07-08 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs, and related tools
US6136040A (en) * 1998-03-05 2000-10-24 Washington University Animal model with disrupted FGF-9 gene
JP2002532126A (ja) 1998-09-14 2002-10-02 スタンフォード ユニバーシティ 関節状態の評価及び損傷防止装置
US7239908B1 (en) 1998-09-14 2007-07-03 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
US20020058036A1 (en) * 1999-07-27 2002-05-16 Michael Jeffers Novel fibroblast growth factor and nucleic acids encoding same
DE20023659U1 (de) 1999-10-06 2005-07-07 Tigenix N.V. Molekulare Marker zum Testen der phänotypischen Stabilität von Zellpopulationen und Zellpopulationen für die autologe Transplantation
EP1282690B9 (en) 1999-10-06 2005-03-02 Tigenix N.V. Isolation of precursor cells and their use for tissue repair
US7482114B2 (en) 1999-10-06 2009-01-27 Tigenix N.V. In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selected cell populations for autologous transplantation
AU2001239765A1 (en) * 2000-02-14 2001-08-27 Smith Kline Beecham Corporation Novel compounds
WO2001068854A2 (en) 2000-03-13 2001-09-20 Amgen, Inc. Fibroblast growth factor-like molecules and uses thereof
EP1322225B1 (en) 2000-09-14 2009-03-25 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
AU2001290887B2 (en) 2000-09-14 2006-06-08 The Board Of Trustees Of The Leland Stanford Junior University Assessing condition of a joint and cartilage loss
AU2002249170B2 (en) * 2001-02-02 2007-02-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V Method for identifying functional nucleic acids
US8439926B2 (en) 2001-05-25 2013-05-14 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
EP1389980B1 (en) 2001-05-25 2011-04-06 Conformis, Inc. Methods and compositions for articular resurfacing
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003076467A1 (en) * 2002-03-14 2003-09-18 Yeda Research And Development Co. Ltd. Compositions and methods for inducing and regulating bone formation
WO2004022095A1 (en) * 2002-09-04 2004-03-18 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
JP2006501977A (ja) 2002-10-07 2006-01-19 コンフォーミス・インコーポレイテッド 関節表面に適合する３次元外形を伴う最小限侵襲性関節インプラント
AU2003290757A1 (en) 2002-11-07 2004-06-03 Conformis, Inc. Methods for determing meniscal size and shape and for devising treatment
AU2011211453B2 (en) * 2004-06-21 2015-01-15 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
CN101506355B (zh) * 2004-09-24 2012-06-27 成血管细胞系统公司 多能扩增间充质前体细胞子代（memp）及其应用
US7391676B2 (en) * 2004-12-22 2008-06-24 Asml Netherlands B.V. Ultrasonic distance sensors
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
US20070049739A1 (en) * 2005-08-30 2007-03-01 Biomet Manufacturing Corp. Method and system for extracting blood-derived growth factors
EP2649951A3 (en) 2006-02-06 2013-12-25 ConforMIS, Inc. Patient selectable joint arthroplasty devices and surgical tools
US8623026B2 (en) 2006-02-06 2014-01-07 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief
KR101503939B1 (ko) * 2007-01-23 2015-03-18 고리츠다이가쿠호진 요코하마시리츠다이가쿠 연골 세포 조제 방법
WO2008101090A2 (en) 2007-02-14 2008-08-21 Conformis, Inc. Implant device and method for manufacture
WO2008157412A2 (en) 2007-06-13 2008-12-24 Conformis, Inc. Surgical cutting guide
US8682052B2 (en) 2008-03-05 2014-03-25 Conformis, Inc. Implants for altering wear patterns of articular surfaces
JP2011519713A (ja) 2008-05-12 2011-07-14 コンフォーミス・インコーポレイテッド 面関節および他の関節の治療のためのデバイスならびに方法
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8808297B2 (en) 2009-02-24 2014-08-19 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
US8808303B2 (en) 2009-02-24 2014-08-19 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
WO2010099231A2 (en) 2009-02-24 2010-09-02 Conformis, Inc. Automated systems for manufacturing patient-specific orthopedic implants and instrumentation
US12383287B2 (en) 2009-02-24 2025-08-12 Microport Orthopedics Holdings, Inc. Systems and methods for installing an orthopedic implant
US9017334B2 (en) 2009-02-24 2015-04-28 Microport Orthopedics Holdings Inc. Patient specific surgical guide locator and mount
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
BRPI1014917A2 (pt) 2009-04-16 2016-04-19 Conformis Inc "dispositivos de artroplastia de junta específica para páciente para reparo de ligamento"
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
WO2011072235A2 (en) 2009-12-11 2011-06-16 Conformis, Inc. Patient-specific and patient-engineered orthopedic implants
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US9486226B2 (en) 2012-04-18 2016-11-08 Conformis, Inc. Tibial guides, tools, and techniques for resecting the tibial plateau
US9675471B2 (en) 2012-06-11 2017-06-13 Conformis, Inc. Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
CA2882881A1 (en) 2013-03-10 2014-09-18 National University Corporation Nagoya University Therapeutic agent for systemic bone disease and use thereof
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
AU2020283377B2 (en) 2019-05-29 2022-08-04 Wright Medical Technology, Inc. Preparing a tibia for receiving tibial implant component of a replacement ankle
JP2020015733A (ja) * 2019-08-19 2020-01-30 アンセルムＩｎｓｅｒｍ 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
IT201900025126A1 (it) * 2019-12-20 2021-06-20 Sildeha Swiss S A Uso di derivati dell’acido ialuronico nella rigenerazione dei tessuti ossei e cartilaginei
WO2021146015A1 (en) 2020-01-17 2021-07-22 Wright Medical Technology, Inc. Guidance tools, systems, and methods
US12440227B2 (en) 2021-02-24 2025-10-14 Wright Medical Technology, Inc. Preparing a tibia for receiving tibial implant component of a replacement ankle
US12582421B2 (en) 2022-05-13 2026-03-24 Wright Medical Technology, Inc. Intraoperative adjustable guides, systems, and methods
CN116162589B (zh) * 2022-12-30 2025-10-03 西北工业大学 干细胞及其制备方法和应用、及标记组合物及其应用
US12569355B2 (en) 2023-08-31 2026-03-10 Wright Medical Technology, Inc. Systems and methods for total ankle arthroplasty

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5226914A (en) * 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5270197A (en) * 1990-12-20 1993-12-14 The Children's Medical Center Corporation Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor
JP3385040B2 (ja) * 1991-02-14 2003-03-10 武田薬品工業株式会社 グリア活性化因子およびその製造法
EP0608546A3 (en) * 1992-12-22 1995-09-27 Takeda Chemical Industries Ltd Glia activating factor (gaf), antibodies against it and their uses.
AU6446194A (en) * 1993-03-17 1994-10-11 Whittier Institute For Diabetes And Endocrinology, The Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof

Also Published As

Publication number Publication date
WO1996041523A1 (en) 1996-12-27
IL122472A0 (en) 1998-06-15
IL122473A0 (en) 1998-06-15
DE69624239T2 (de) 2003-07-10
EP0836380A1 (en) 1998-04-22
CA2223701A1 (en) 1996-12-27
DE69619526T2 (de) 2002-10-31
US6447783B1 (en) 2002-09-10
EP0833620A1 (en) 1998-04-08
ES2183957T3 (es) 2003-04-01
JPH11508358A (ja) 1999-07-21
AU721773B2 (en) 2000-07-13
AU715996B2 (en) 2000-02-17
EP0836380A4 (en) 1999-03-31
ATE213590T1 (de) 2002-03-15
EP1342476A2 (en) 2003-09-10
ATE225652T1 (de) 2002-10-15
EP1342476A3 (en) 2003-09-17
CA2223701C (en) 2010-02-16
EP0833620A4 (da) 1998-05-06
EP0833620B1 (en) 2002-10-09
IL122472A (en) 2003-11-23
DK0836380T3 (da) 2002-04-22
DE69624239D1 (de) 2002-11-14
ES2173289T3 (es) 2002-10-16
CA2224229A1 (en) 1996-12-27
JP2004305221A (ja) 2004-11-04
DE69619526D1 (de) 2002-04-04
EP0836380B1 (en) 2002-02-27
JPH11507828A (ja) 1999-07-13
WO1996041620A1 (en) 1996-12-27
JP3673281B2 (ja) 2005-07-20
US20020193309A1 (en) 2002-12-19
AU6014496A (en) 1997-01-09
AU6014596A (en) 1997-01-09
CN1195982A (zh) 1998-10-14
IL122473A (en) 2003-11-23

Similar Documents

Publication Publication Date Title
DK0833620T3 (da) FGFR3, en markør for mesenkymale progenitorceller
ATE240729T1 (de) Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle
ATE198980T1 (de) Bioabbaubare polymere zur zelltransplantation
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
YU5396A (sh) Novi biološki aktivni proteini, njihove farmaceutske formulacije i postupak za njihovo dobijanje
DE69625518D1 (de) Wirkstoff zur behandlung neurodegenerativer störungen
ATE296642T1 (de) Reverse-phase zusamensetzung zur bindegewebsreparatur
BR0313197A (pt) Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
AU3142597A (en) Dha-pharmaceutical agent conjugates
NZ225344A (en) 3-demethylmevalonic acid derivatives and lactones and pharmaceutical compositions; intermediates for the preparation thereof
BR0214217A (pt) Aumento de função de órgão
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
TR199901433T2 (xx) Pirolo$3,4-D] pirimidinon t�revleri ve bunlar�n ila� olarak kullan�mlar�.
CA2325842A1 (en) Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
DK1007566T3 (da) Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf
ATE222122T1 (de) Verfahren zur tötung von zielzellen in geernteten zellpopulationen mit hilfe von zwei immunotoxinen
EP1080724A4 (en) COMPOSITIONS FOR REDUCING MTP ACTIVITY
DE69737455D1 (de) Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben
CA2069638A1 (en) Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
PL361732A1 (en) Use of a biological material containing three-dimensional scaffolds of hyaluronic acid derivatives for the preparation of implants in arthroscopy and kit for instruments for implanting said biological material by arthroscopy
FR2768145B1 (fr) Nouveaux composes derives d'acide alkylene diamine di- ou tri-acetique, leur procede de preparation, leur utilisation dans des compositions cosmetiques et pharmaceutiques, et compositions les comprenant
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
WO2002012336A3 (en) TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
Smart et al. Effect of dietary ascorbate on covalent binding of benzene to bone marrow and hepatic tissue in vivo